New drug combo tested in fight against tough leukemia in young adults
NCT ID NCT03571321
Summary
This early-stage study aims to find out if adding a drug called ruxolitinib to standard chemotherapy is safe and tolerable for adolescents and young adults (ages 18-40) newly diagnosed with a specific, hard-to-treat form of acute lymphoblastic leukemia (ALL). The main goal is to check for side effects when the drugs are combined. Researchers will also look at whether this combination helps patients achieve a deeper remission and live longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.